Terns Pharmaceuticals, Inc.
TERN
주식 순위
#3581
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
주가
$52.95
마지막 동기화: 2026-05-15
시가총액
$4.77B
변동 (1일)
0.00%
변동 (1년)
552.09%
국가
US
거래 Terns Pharmaceuticals, Inc. (TERN)
카테고리
Healthcare
Terns Pharmaceuticals, Inc. (TERN)의 주가 이력
최고 종가: $52.95 (2026-05-01 기준)
최저 종가: $20.53 (2021-02-01 기준)
최저 종가: $20.53 (2021-02-01 기준)
Terns Pharmaceuticals, Inc.의 주가 이력 (2021 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -1.17% |
| 2025 | 517.55% |
| 2024 | -2.74% |
| 2023 | -12.48% |
| 2022 | 13.79% |
| 2021 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $520.49 | 22.10% |
US
|
|
| $249.07 | 806.04% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $886.21 | 6.16% |
NL
|
|
| $752.87 | 7.40% |
CH
|
